Literature DB >> 11119593

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

G Carcelain1, R Tubiana, A Samri, V Calvez, C Delaugerre, H Agut, C Katlama, B Autran.   

Abstract

Immune control of human immunodeficiency virus (HIV) is not restored by highly active antiretroviral therapies (HAART) during chronic infection. We examined the capacity of repeated structured therapeutic interruptions (STI) to restore HIV-specific CD4 and CD8 T-cell responses that controlled virus production. Eleven STI (median duration, 7 days; ranges, 4 to 24 days) were performed in three chronically HIV-infected patients with CD4 counts above 400/mm(3) and less than 200 HIV RNA copies/ml after 18 to 21 months of HAART; treatment resumed after 1 week or when virus became detectable. HIV-specific T-cell responses were analyzed by proliferation, gamma interferon (IFN-gamma) production, and enzyme-linked immunospot assays. Seven virus rebounds were observed (median, 4,712 HIV-1 RNA copies/ml) with a median of 7 days during which CD4 and CD8 counts did not significantly change. After treatment resumed, the viral load returned below 200 copies/ml within 3 weeks. Significant CD4 T-cell proliferation and IFN-gamma production against HIV p24 appeared simultaneously with or even before the virus rebounds in all patients. These CD4 responses lasted for less than 3 weeks and disappeared before therapeutic control of the virus had occurred. Increases in the numbers of HIV-specific CD8 T cells were delayed compared to changes in HIV-specific CD4 T-cell responses. No delay or increase in virus doubling time was observed after repeated STI. Iterative reexposure to HIV during short STI in chronically infected patients only transiently mobilized HIV-specific CD4 T1-helper cells, which might be rapidly altered by virus replication. Such kinetics might explain the failure at delaying subsequent virus rebounds and raises concerns about strategies based on STI to restore durable HIV-specific T-cell responses in chronic HIV infection.

Entities:  

Mesh:

Year:  2001        PMID: 11119593      PMCID: PMC113917          DOI: 10.1128/JVI.75.1.234-241.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.

Authors:  A U Neumann; R Tubiana; V Calvez; C Robert; T S Li; H Agut; B Autran; C Katlama
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

2.  Control of HIV despite the discontinuation of antiretroviral therapy.

Authors:  J Lisziewicz; E Rosenberg; J Lieberman; H Jessen; L Lopalco; R Siliciano; B Walker; F Lori
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

3.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.

Authors:  C J Pitcher; C Quittner; D M Peterson; M Connors; R A Koup; V C Maino; L J Picker
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

4.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.

Authors:  A Oxenius; D A Price; P J Easterbrook; C A O'Callaghan; A D Kelleher; J A Whelan; G Sontag; A K Sewell; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

5.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.

Authors:  M Larsson; X Jin; B Ramratnam; G S Ogg; J Engelmayer; M A Demoitie; A J McMichael; W I Cox; R M Steinman; D Nixon; N Bhardwaj
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

6.  Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.

Authors:  O Pontesilli; S Kerkhof-Garde; D W Notermans; N A Foudraine; M T Roos; M R Klein; S A Danner; J M Lange; F Miedema
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

7.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.

Authors:  T S Li; R Tubiana; C Katlama; V Calvez; H Ait Mohand; B Autran
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

8.  Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Authors:  C M Gray; J Lawrence; J M Schapiro; J D Altman; M A Winters; M Crompton; M Loi; S K Kundu; M M Davis; T C Merigan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

9.  Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

Authors:  C R Rinaldo; J M Liebmann; X L Huang; Z Fan; Q Al-Shboul; D K McMahon; R D Day; S A Riddler; J W Mellors
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

10.  Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P Moss; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; A Hurley; M Markowitz; D D Ho; A J McMichael; D F Nixon
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  21 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 2.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

3.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

4.  Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

5.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA.

Authors:  Samantha S Soldan; Matthew L Plassmeyer; Meghan K Matukonis; Francisco González-Scarano
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  A case of multiorgan failure following interruption of antiretroviral treatment.

Authors:  M Crespo; J C Paradiñeiro; E Ribera; I Ruiz; V Falcó; J Lopez-Quiñones; I Ocaña; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

9.  Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.

Authors:  William Borkowsky; Ram Yogev; Petronella Muresan; Elizabeth McFarland; Lisa Frenkel; Terry Fenton; Edmond Capparelli; Jack Moye; Paul Harding; Nina Ellis; Barbara Heckman; Joyce Kraimer
Journal:  Vaccine       Date:  2008-01-04       Impact factor: 3.641

10.  Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Li-Yun Zou; Wei Zhou
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.